Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Proteins Identified in Metastatic Kidney Cancer

By LabMedica International staff writers
Posted on 20 Dec 2012
A unique set of proteins have been analyzed that are likely to be involved in the spread of metastatic renal cell carcinoma (RCC). More...


The discovery will help physicians recognize which tumors are going to behave more aggressively and provide those patients with more intensive treatment and closer follow-up.

Scientists collaborating with pathologists at St. Michael's Hospital (Toronto, ON, Canada) used differential proteomics with isobaric tags for relative and absolute quantitation (iTRAQ) labeling and liquid chromatography and mass spectrometry (LC-MS/MS) analysis to identify proteins that are differentially expressed in metastatic compared to primary RCC. Primary RCC tissues and matched normal kidney tissues from the same patient were obtained from nephrectomy specimens at the hospital and processed.

Western blot analysis, tissue microarray construction and immunohistochemistry were also performed. The team identified 29 proteins that change when cancer cells spread from the original site of the kidney tumor and all 29 proteins have been previously been linked to other malignancies. Of these, 12 were overexpressed (iTRAQ ratios of equal or greater than 1.5) and 17 were under expressed (iTRAQ ratios of equal to or less than 0.67).

The authors concluded that through quantitative proteomic analysis, they had identified differential protein expressions that can distinguish between aggressive and nonaggressive RCC tumors. Many of these proteins are involved in biological pathways pertinent to tumor progression and metastasis. In addition, their preliminary analysis showed that some of these dysregulated proteins may be useful clinical markers and validation of these markers would greatly improve RCC patient treatment and increase overall survival.

George M. Yousef, MD, PhD, the senior author of the study, said “Metastatic renal cell carcinoma is one of the most treatment-resistant malignancies and patients have dismal prognosis. Identification of markers that can predict the potential of metastases will have a great impact on improvement patient outcomes." The study was published on October 17, 2012, in the journal Molecular & Cellular Proteomics.

Related Links:

St. Michael's Hospital




Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.